A round of Series A funding has pulled in $5 million for Singapore-based diagnostics company One BioMed, which intends to use the proceeds to fund commercialization of its automated sample preparation diagnostic platform for nucleic acid purification and isolation.
Funding round pulls in $5M for One BioMed
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.